FRI0111 Anti-citrullinated protein antibody reactivities in treatment naÏve early rheumatoid arthritis
| Autor: | A-B Aga, B.-T.S. Fevang, Joseph O. Sexton, Monika Hansson, Linda Mathsson-Alm, Aase Haj Hensvold, Espen A Haavardsholm, Anca I. Catrina, Siri Lillegraven, M.K. Jonsson |
|---|---|
| Rok vydání: | 2017 |
| Předmět: |
musculoskeletal diseases
030203 arthritis & rheumatology medicine.medical_specialty biology business.industry Anti–citrullinated protein antibody Early rheumatoid arthritis Fibrinogen INCEPTION COHORT Gastroenterology Therapy naive 03 medical and health sciences 0302 clinical medicine immune system diseases Internal medicine Early ra biology.protein Medicine In patient 030212 general & internal medicine Antibody skin and connective tissue diseases business medicine.drug |
| Zdroj: | Poster Presentations. |
| Popis: | Background An increase in the number of anti-citrullinated protein antibodies (ACPA) reactivities precede RA onset, and may be involved in the pathogenesis of the disease. The presence of ACPA is associated with radiographic progression in RA, and it has been suggested that ACPAs with different reactivities may be associated with different phenotypes of RA. Objectives To assess the prevalence of baseline ACPA reactivities in an inception cohort of early RA patients, including subgroups based on anti-CCP/RF status, and to compare the findings to healthy controls. Methods 217 DMARD-naive early RA patients from the ARCTIC trial (1) were analysed. Radiographs were scored according to van der Heijde Sharp (vdHS) score. Anti-CCP status was analysed by FEIA (pos. if ≥10 IU/mL) and RF by ELISA (pos. if ≥25 IU/mL). ACPA titres (AU/ml) were considered pos. if above the 98-perc. of values in 619 non-RA subjects. Analysis of 13 ACPA reactivities targeting citrullinated peptides from fibrinogen, alpha-1 enolase, vimentin, fillagrin and histone was performed at baseline in patients and 94 controls (blood donors matched for age/gender/smoking), using a multiplex chip-based assay (2). Results Baseline characteristics are presented in the table. The figure shows the prevalence of ACPA reactivities in the subgroups, with median [IQR] number of antibody reactivities in all patients 7 [3,10], compared to 0 [0,0] in controls (p Conclusions Prevalence of ACPA reactivities differed in subgroups of DMARD-naive early RA patients according to anti-CCP and RF status. All RA subgroups, including RF- and anti-CCP- patients, had higher prevalence of ACPA reactivities compared to healthy controls. References Haavardsholm et al BMJ 2016. Hansson et al Arthr Res Ther 2012. Disclosure of Interest M. Jonsson: None declared, A. Hensvold: None declared, M. Hansson: None declared, L. Mathsson-Alm Employee of: Thermo Fisher Scientific, A.-B. Aga: None declared, J. Sexton: None declared, B.-T. Fevang Grant/research support from: Novartis, S. Lillegraven: None declared, A. Catrina: None declared, E. Haavardsholm Grant/research support from: AbbVie, MSD, Pfizer, Roche, UCB |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|